1. Home
  2. AZTA vs NTLA Comparison

AZTA vs NTLA Comparison

Compare AZTA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azenta Inc.

AZTA

Azenta Inc.

N/A

Current Price

$45.33

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$9.91

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AZTA
NTLA
Founded
1978
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
AZTA
NTLA
Price
$45.33
$9.91
Analyst Decision
Buy
Buy
Analyst Count
6
20
Target Price
★ $43.40
$22.78
AVG Volume (30 Days)
888.9K
★ 4.0M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.43
EPS
N/A
★ N/A
Revenue
★ $593,821,000.00
$67,671,000.00
Revenue This Year
$4.54
N/A
Revenue Next Year
$5.36
$174.74
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 16.92
52 Week Low
$15.93
$7.95
52 Week High
$50.06
$18.48

Technical Indicators

Market Signals
Indicator
AZTA
NTLA
Relative Strength Index (RSI) 60.58 39.58
Support Level $31.51 N/A
Resistance Level $46.41 $13.59
Average True Range (ATR) 2.58 0.88
MACD 0.68 -0.16
Stochastic Oscillator 65.51 5.63

Price Performance

Historical Comparison
AZTA
NTLA

About AZTA Azenta Inc.

Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: